Trial Details

COMPLETED
Basic Information
Clinical ID c1217
Identifier NCT05389709
Trial Title A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia|Irritable Bowel Syndrome|Functional Dyspepsia
Interventions DRUG: Iberogast (STW5-II, BAY98-7410)
Participant Information
Sponsor Bayer
City Many Locations
Country/Region Germany
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type OBSERVATIONAL
Phase NULL
Time Information
Start Date 2022-06-04
Primary Completion Date 2023-05-11
Completion Date 2023-05-11